1365970-03-1

Basic information

• Product Name: Glecaprevir
• Synonyms: Glecaprevir;(33R,35S,91R,92R,5S,E)-5-(tert-butyl)-N-((1R,2R)-2-(difluoromethyl)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)cyclopropyl)-14,14-difluoro-4,7-dioxo-2,8,10-trioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopentanacyclotetradecaphan-12-ene-35;ABT-493;Glecaprevir(ABT-493)
• CAS NO: 1365970-03-1
• Molecular Formula: C38H46F4N6O9S
• Molecular Weight: 838.8652528
• Mol File: 1365970-03-1.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.46±0.1 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.46±0.40(Predicted)
• CAS DataBase Reference: Glecaprevir(CAS DataBase Reference)
• NIST Chemistry Reference: Glecaprevir(1365970-03-1)
• EPA Substance Registry System: Glecaprevir(1365970-03-1)

Safety Data

• Hazardous Substances Data: 1365970-03-1(Hazardous Substances Data)

Usage

Description

Glecaprevir is an antiviral medication specifically designed to target and inhibit the hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease. This enzyme plays a crucial role in the replication and assembly of the virus within host cells. Developed collaboratively by AbbVie and Enanta Pharmaceuticals, Glecaprevir has demonstrated potent antiviral activity against various HCV genotypes and offers a high barrier to resistance in vitro. It is particularly beneficial for patients with chronic kidney disease who are also suffering from HCV.

Uses

Used in Hepatitis C Treatment:
Glecaprevir is used as an antiviral agent for the treatment of patients with hepatitis C virus (HCV) genotypes 1-6. It is particularly effective in treating patients with chronic kidney disease who are also infected with HCV, providing a much-needed therapeutic option for this vulnerable population.
Used in Chronic Hepatitis C Infection:
Glecaprevir is used as a component in a co-formulation with an HCV NS5A inhibitor, pibrentasvir. This combination therapy has shown significant antiviral activity against major HCV genotypes, offering a potent treatment option for patients with chronic hepatitis C infection.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Glecaprevir is used as a key ingredient in the development of new antiviral drugs targeting the hepatitis C virus. Its potent antiviral properties and high barrier to resistance make it a valuable asset in the ongoing fight against HCV and its associated health complications.

Approval

On 19 December 2016, AbbVie submitted a new drug application to the U.S. Food and Drug Administration for the glecaprevir/pibrentasvir (trade name Mavyret) regimen for the treatment of all major genotypes of chronic hepatitis C. On 3 August 2017 the FDA approved the combination for hepatitis C treatment. In Europe, it was approved on 17 August 2017 for the same indication, under the trade name Maviret.

Side effects

The most common adverse effects, observed in at least 10% of phase 3 trial participants, were headache and fatigue.